MeiraGTx (MGTX) announced two abstract presentations at the Association for Research in Vision and Ophthalmology, ARVO, 2023 Annual Meeting. The first abstract will present humoral immune response data from the Company’s Phase 1/2 MGT009 trial for the investigational gene therapy botaretigene sparoparvovec in patients with the inherited retinal disease X-linked retinitis pigmentosa associated with the retinitis pigmentosa GTPase regulator gene which is being developed along with our partners Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ). The second abstract will present data from MeiraGTx’s proprietary promoter platform involving the use of novel, AI-assisted engineered promoters to improve gene expression in rod photoreceptors.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MGTX:
- MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
- MeiraGTx to Participate in Upcoming Investor Conferences
- MeiraGTx price target lowered to $22 from $27 at RBC Capital
- MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
- MeiraGTx expects cash to fund requirements into 4Q24